Cardiovascular Medicine and Haematology articles for Canada

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 204

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 1.00
Human heart-on-a-chip model emulates structural and functional characteristics of diastolic dysfunction and reveals a beneficial role for senolytics 1.00
1 0.17
Raman Microscopy at the Organic–Inorganic Interfaces in Human Calcified Aortic Valves Shows the Co-Existence of Whitlockite Crystals and Carbonated Hydroxyapatite-Mineralized Collagen Fibrils 0.17
1 0.05
Bi-allelic variants in POPDC2 cause an autosomal recessive syndrome presenting with cardiac conduction defects and hypertrophic cardiomyopathy 0.05
1 0.95
Exploratory study of prognostic plasma biomarkers in patients with pulmonary arterial hypertension 0.95
13 4.32
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.01
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension 0.04
Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future Exacerbations 0.13
Patient Factors and Clinical Efficacy of Early Identification and Treatment of COPD and Asthma. 1.00
Outcomes of a Typical Fibrotic Hypersensitivity Pneumonitis Pattern on Chest Computed Tomography 0.78
Mucus Plugs Correlate with Small Airway Remodelling in Asthma: A Case-Control Study. 0.67
Distinct Morphological Types of Small Airway Obstructions in Smokers with Emphysema and End-Stage COPD. 0.08
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. 0.06
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study 0.01
Clinical Remission by a Comprehensive Severe Asthma Management Strategy Guided by Airway Inflammometry and Bioimaging. 1.00
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis. 0.29
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. 0.17
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE) 0.08
1 0.11
Intraoperative Cardiac Events in Pediatric Patients with Congenital Heart Disease Undergoing Noncardiac Procedures: Analysis of a Large Multicenter Registry. 0.11
1 0.17
Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk : A Target Trial Emulation Study. 0.17
1 0.13
Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial 0.13
1 0.15
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis 0.15
2 0.30
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients with Eosinophilic Granulomatosis with Polyangiitis 0.13
Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations 0.17
5 1.41
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma 0.03
Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF 0.04
Somatic IRF4 Mutations and Thymic Tropism in Primary Mediastinal Large B-cell Lymphoma 0.94
Destabilization of PF4-antigenic complexes in heparin-induced thrombocytopenia 0.31
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL 0.09
2 0.36
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis 0.10
Dominant rhabdomyolysis linked to a recurrent ATP2A2 variant reducing SERCA2 function in muscle 0.26
1 0.03
<atl>Open surgery iversus/i branched endovascular repair of the aortic arch in residual dissections after type A surgical repair</atl> 0.03
1 0.02
Distinct follicular T cell subsets regulate lymphoma progression and outcomes 0.02
11 5.67
A Randomized, Placebo-Controlled, Double-Blind, Crossover Trial of Inhaled Nitric Oxide in Patients With Mild-to-Severe COPD 0.96
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers 0.05
Twelve-month follow-up and economic evaluation of an alternative care provider clinic for severe sleep-disordered breathing 1.00
Recovery rate from exertional desaturation is associated with disease progression and mortality risk in patients with fibrotic interstitial lung disease 0.45
Structural and functional pulmonary MRI to predict pulmonary exacerbations in Cystic Fibrosis 0.20
International stakeholder engagement on clinical care and research for sleep assessment and nocturnal hypoxaemia in pulmonary fibrosis 0.06
Breathlessness abnormality is best assessed at peak exercise during incremental cardiopulmonary cycle exercise testing 0.80
Geographical Distribution of Phase II/III Pharmaceutical Randomised Controlled Trials in Adults with Interstitial Lung Disease 0.17
Sputum Cellularity and MRI Ventilation Defects in Severe Asthma 1.00
Prediction pathway for severe asthma exacerbations: a Bayesian Network analysis 0.05
Association between a Recalled Positive Airway Pressure (PAP) Device and Obstructive Lung Disease: A Province-Based Study 0.93
14 3.35
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. 0.03
A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension. 0.85
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin. 0.08
Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome. 1.00
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome 0.09
Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy. 0.05
Short-Term Anticoagulation versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial. 0.54
Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. 0.38
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. 0.11
Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. 0.03
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.02
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis 0.03
The Impact of Fontan Circulatory Failure on Heart Transplant Survival: A 20-Center Retrospective Cohort Study. 0.04
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. 0.12
1 0.67
Decreased Clearance of Low-Density Lipoprotein Cholesterol is Causally Associate With Increased Mortality of Septic Shock. 0.67
2 0.14
Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV 0.08
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. 0.06
4 2.74
Differential Reductions in Total and Compositional PM2.5 Exposure across Socioeconomic and Demographic Groups from Emission Source Mitigation in Canada (2007–2016) 0.71
Finer Particulate Matter Exposure Disparities Exist but Vary across Pollution Concentrations 0.40
Reflection of Sectoral Emissions on Air Quality, Mortality, and Air Pollution Exposure Inequalities in a Metropolitan Context 0.86
Implications of Off-Peak Commercial Deliveries for Air Quality and Environmental Justice 0.77
19 4.61
New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort 0.77
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.01
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis 0.03
SLC4A3-related short QT syndrome assessed in human induced pluripotent stem cell-derived cardiomyocytes: mechanisms of ventricular arrhythmia and sudden cardiac death 0.07
Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis 0.06
Arrhythmias in congenitally corrected transposition of the great arteries: an international study 0.19
Foundation models for electrocardiogram interpretation: clinical implications 0.59
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.11
Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting 0.50
Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study 0.06
Outcomes of moderate mixed aortic valve stenosis and regurgitation 0.32
Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation 0.02
Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging 0.38
ApoB and Lp(a): core measures to assess cardiovascular risk 0.83
Colchicine for secondary prevention of vascular events: a meta-analysis of trials 0.22
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis 0.28
Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease 0.08
First myocardial infarction: risk factors, symptoms, and medical therapy 0.07
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.02
1 0.22
Adherence to positive airway pressure therapy and healthcare resource utilization and costs among patients with obstructive sleep apnea and obesity 0.22
2 1.25
Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease 0.25
Tiotropium Initiation and Dementia Risk in Chronic Obstructive Pulmonary Disease 1.00
9 1.50
Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy 0.20
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes 0.00
Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease 0.02
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia 0.08
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.04
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.04
Proactive vs Reactive Treatment of Hypotension During Surgery 0.08
A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease 0.06
Antihypertensive Medication Timing and Cardiovascular Events and Death 0.98
2 1.82
ARF6 controls VSMC phenotypic switching upon lipid stimulation to promote inflammatory signaling contributing to the progression of atherosclerosis 0.88
Platelet Jak2 deficiency accelerates atherosclerosis with increased inflammatory response 0.94
3 0.60
Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by combined 𝜷-adrenergic + cholinergic agonists 0.15
Loss of RPGR disrupts motile cilia and causes primary ciliary dyskinesia by affecting F-actin dynamics 0.41
Clonal hematopoiesis activates pro-calcific pathways in macrophages and promotes aortic valve stenosis 0.03
5 0.25
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. 0.08
Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. 0.04
Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 0.06
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). 0.04
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. 0.05
7 2.30
Females exhibit greater cardiac volume reductions with expiratory muscle loading during submaximal exercise compared to males 0.71
Ventilatory stimulation with relative external dead space loading does not impact sex differences in exertional dyspnoea 1.00
In silico predictions of action potential propagation in doxorubicin cardiotoxicity: A parametric study using preclinical 3D magnetic resonance imaging-based fibrotic left ventricle models 0.06
Mechanistic insights into sex differences in atrial electrophysiology and arrhythmia vulnerability through sex‐specific computational models 0.05
Mathematical model of the zebrafish ventricular cardiomyocyte action potential and calcium transient 0.33
Computational modelling of the pro‐ and antiarrhythmic effects of atrial high rate‐dependent trafficking of small‐conductance calcium‐activated potassium channels 0.08
Computational modelling of cardiac fibroblast signalling reveals a key role for Ca2+ in driving atrial fibrillation‐associated fibrosis 0.06
13 7.53
Impact of reoperation on very long-term survival in patients with failed mitral valve repair: A 30-year single-center Canadian experience 1.00
The influence of reoperation on aortic arch reconstructive surgery: Evidence from a multicenter, national registry 0.81
Comparison of myocardial mechanics after mitral valve repair with leaflet preservation versus leaflet resection: A subanalysis of the randomized Canadian Mitral Research Alliance CardioLink-2 trial 0.93
Single Incision Minimally Invasive Congenital Heart Surgery – Insights into Program Development and Outcome 1.00
Iatrogenic aortic dissection: Insights from the International Registry of Acute Aortic Dissection 0.06
Association of increased red blood cell distribution width with adverse cardiorenal outcomes after cardiac surgery 0.63
Unplanned reinterventions after congenital cardiac surgery and hospital mortality: A report from the Pediatric Cardiac Critical Care Consortium (PC4) 0.03
Pulmonary valve repair at the time of the Ross procedure: a safe and durable strategy to address post-implantation aortic regurgitation 0.44
Extra-cardiac conduit restriction is associated with increased liver fibrosis in adolescent Fontan patients 1.00
Role of primary sternal closure in early outcomes following the Norwood procedure 1.00
Oral anticoagulation in patients with atrial fibrillation and heart valve prosthesis: a substudy from the LAAOS III Trial 0.50
The American Association for Thoracic Surgery (AATS) 2025 Expert Consensus Document: Management of Ebstein anomaly in children and adults 0.06
The American Association for Thoracic Surgery (AATS) 2025 Expert Consensus Document: Surgical management of mitral annular calcification 0.07
17 3.56
Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation 0.83
Single-Ventricle Disease 0.06
Use of the Ross Procedure in North America 0.54
Pulsed-Field Ablation to Enhance the Durability of Pulmonary Vein Isolation and Treat Paroxysmal Atrial Fibrillation 0.14
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.06
Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial 1.00
Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction 0.06
Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial 0.12
Sex Differences in Effectiveness of Semaglutide in Patients with Peripheral Artery Disease: The STRIDE Trial 0.10
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial 0.06
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.04
Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease Results From MINDS-ACHD 0.05
Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction The SOGALDI-PEF Trial 0.04
Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050 A Modeling Study 0.25
Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome 0.08
Long-Acting Factor XI Inhibition and Periprocedural Bleeding An Analysis From AZALEA-TIMI 71 0.11
Valve Under-Expansion and Clinical Outcomes with ACURATE neo2: Findings from the ACURATE IDE Trial 0.04
2 0.10
Polygenic risk of coronary artery disease for long-term survivors of breast cancer 0.07
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 0.04
2 0.31
A neuronal architecture underlying autonomic dysreflexia 0.25
Detecting structural heart disease from electrocardiograms using AI 0.06
13 2.91
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases 0.02
Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis 0.08
Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice 0.13
Risk factors for mortality in patients with kidney failure on hemodialysis identified by proteomic analysis of CRIC and PACE studies 0.03
Crystal structures of Ryanodine Receptor reveal dantrolene and azumolene interactions guiding inhibitor development 0.13
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma 0.11
Equitable cleanup of Superfund sites leaving no U.S. community behind 0.20
Hypoxic conditioning in Parkinson’s disease: randomized controlled multiple N-of-1 trials 0.29
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models 0.07
Biomarker panels for improved risk prediction and enhanced biological insights in patients with atrial fibrillation 0.05
Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents 0.86
Association between self-reported multimorbidity and longitudinal brain Aβ deposition in Alzheimer’s disease 0.06
Metabolic reprogramming of the neovascular niche promotes regenerative angiogenesis in proliferative retinopathy 0.88
1 0.03
Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease 0.03
7 2.35
Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia 0.03
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial 0.13
Remote monitoring of heart failure exacerbations using a smartwatch 1.00
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial 0.04
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial 0.98
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.01
Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial 0.15
1 0.92
Lipid raft proteomics identify endothelial myosin-9 (MYH9) as a regulator of low-density lipoprotein transcytosis and atherosclerosis 0.92
2 1.11
Association of CT Features with Radiologic Patterns in Interstitial Lung Disease: Multinomial Analysis in CARE-PF. 0.97
Seven-year Prognostic Value of Coronary CT Angiography-derived Fractional Flow Reserve in Stable Angina. 0.14
1 0.21
Deep-learning analysis of 3D microarchitectural remodeling in hypertrophic cardiomyopathy 0.21
1 0.09
PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation 0.09
1 0.86
Selective translation of ZNF281 as part of the integrated stress response system has therapeutic relevance for cardio-oncology 0.86
1 1.00
Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial 1.00
1 0.06
Genetic characterization of preschool wheeze phenotypes 0.06
9 1.79
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 0.05
Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials 0.39
Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial 0.08
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial 0.63
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.03
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.07
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial 0.43
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial 0.04
ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial 0.07
1 0.19
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial 0.19
1 1.00
Extended CT angiography versus standard CT angiography for the detection of cardioaortic thrombus in patients with ischaemic stroke and transient ischaemic attack (DAYLIGHT): a prospective, randomised, open-label, blinded end-point trial 1.00
10 1.81
Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation 0.06
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial 0.10
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease 0.06
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy 0.10
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism 0.66
Medical Management and Revascularization for Asymptomatic Carotid Stenosis 0.05
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 0.04
Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation 0.59
Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years 0.10
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype 0.06
8 3.78
Association of blood eosinophils and exhaled nitric oxide with exacerbations in patients with asthma, COPD and asthma+COPD: the NOVELTY study 0.07
Development and validation of the Hypersensitivity Pneumonitis South Asian Questionnaire for Exposure (HP-SAQE): a novel, qualitative and quantitative tool 0.02
Extreme value analysis has the potential to improve spirometry interpretation 1.00
Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD 0.43
Heterogeneity of short-term elexacaftor-tezacaftor-ivacaftor response in cystic fibrosis using 129Xe MRI 1.00
Serum IgA isotypes are associated with percent emphysema, wall thickness and lung function decline 0.03
Factors associated with guideline-concordant maintenance inhaled medication for COPD: a population-based, longitudinal cohort study 0.95
Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis 0.27

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.